fulvestrant has been researched along with Experimental Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, A; Li, G; Ren, C; Wang, G; Yang, T; Yu, Z; Zhang, Q | 1 |
| Antoon, JW; Beckman, BS; Burow, ME; Collins-Burow, B; David, O; Elliott, S; Lai, R; Martin, EC; Nam, SY; Nephew, KP; Nitzchke, AM; Rhodes, LV; Salvo, VA; Shan, B; Tang, Y; Wang, G; Xiong, W | 1 |
| Dolcet, X; Domingo, M; Dosil, MA; Eritja, N; Llombart-Cussac, A; Matias-Guiu, X; Mirantes, C; Santacana, M; Valls, J | 1 |
| Chang, C; Han, R; Hsu, I; Li, Y; Messing, EM; Niu, Y; Shang, Z; Tian, J; Wen, S; Yeh, S; Zhang, M | 1 |
| Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA | 1 |
| Annable, T; Collins, KI; Frost, P; Greenberger, LM; Komm, BS; Lyttle, CR; Miller, CP; Satyaswaroop, PG; Zhang, Y | 1 |
6 other study(ies) available for fulvestrant and Experimental Neoplasms
| Article | Year |
|---|---|
RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer.
Topics: Animals; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Down-Regulation; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Nuclear Proteins; Structure-Activity Relationship; Transcription Factors; Tumor Cells, Cultured | 2017 |
MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinogenesis; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase 5; Mice; Mitogen-Activated Protein Kinase 7; Neoplasms, Experimental; RNA, Small Interfering; Signal Transduction | 2013 |
Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, SCID; Mutation; Neoplasms, Experimental; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Butylhydroxybutylnitrosamine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Integrin alpha5beta1; Interleukin-6; Macrophages; Mice; Neoplasms, Experimental; Treatment Outcome; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2016 |
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Topics: Animals; Binding, Competitive; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Organ Size; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Sensitivity and Specificity; Tamoxifen; Time Factors; Tumor Cells, Cultured; Uterus; Xenograft Model Antitumor Assays | 2001 |